Hope: By the end of the year, the needleless vaccine will come, know why this new vaccine is important

 

Vaccines that do not require a needle to apply and which can be saved even at normal temperatures will be available for use by the end of the year, effective in preventing corona infection. World Health Organization (WHO) senior scientist Soumya Swaminathan gave this information in an interview.

According to Swaminathan, by the end of 2021, clinical trials of six to eight new vaccines will be completed. Drug regulatory bodies will also deal with their safety assessment. This will increase the number of competent vaccines from 16 to 18, from the current ten to be able to compete with Kovid-19 in early 2022.

So it is important to have new vaccine -
Sars-Cove-2 virus is changing in new form of cases - The
vaccine manufacturer is facing difficulties in meeting the demand -
Vaccination has been started in 122 countries only at the moment. 

Available in the form of sprays or patches,
Swaminathan said that most of the new vaccines are based on alternative technology and supply systems. They will be transported either through the nose spray or through the nose with the help of bandage to the body through the skin. These vaccines will make Kovid-19 vaccination easier for people in other vulnerable groups, including pregnant women.

According to the large-scale
trials, Swaminathan, clinical trials are underway in more than 80 vaccines worldwide. Most of them are going through an early trial. Some vaccines may also prove to be unsuccessful in this. At the same time, many companies have started assessing the impact of the enhanced form of vaccine, so that the new form of corona can be dealt with.

Efforts to assess the impact of a single dose The
experts at the WHO are trying to find out if people who have coronate JD need a second dose. Some studies have indicated that the infection produces immunity against the SARS-Cove-2 virus in the same manner as with the first dose of the vaccine.

Vaccination will
gain speed A dose of Kovid-19 vaccine can be used in immunization of others if a sufficient dose is effective to develop immunity. However, for many countries this process will prove to be extremely challenging. They will need to check the level of antibodies from the blood test to determine whether the work will be done without the second dose being given to the beneficiary.